18 recruiting, 16 completed, 6 active not recruiting, 5 not yet recruiting. 48 Phase 1, 15 Phase 2.
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases QT-019C - SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-01-01 | 2026-01-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-04 | 2026-10-21 |
| The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis CAR-T Therapy - ANCA Associated Vasculitis (AAV) | Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2025-07-01 | 2025-06-24 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases OL-108 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Recruiting | Beijing GoBroad Hospital | 44 | 2025-06-01 | 2025-05-20 |
| A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 12 | 2025-05-19 | 2026-10-21 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases UCAR T-cell - Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2025-02-11 | 2025-09-29 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease ADI-001, Fludarabine, Cyclophosphamide - Lupus Nephritis, Autoimmune Diseases | Phase 1 | Enrolling by invitation | Adicet Therapeutics | 180 | 2024-11-10 | 2026-03-19 |
Showing 20 of 48. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (38) · Lupus Erythematosus, Systemic (21) · Myositis (18) · Scleroderma, Systemic (16) · Granulomatosis with Polyangiitis (10) · Lupus Nephritis (10) · Vasculitis (9) · Autoimmune Diseases (8) · Antiphospholipid Syndrome (7) · Sjogren's Syndrome (7) · Scleroderma, Diffuse (5) · Arthritis, Rheumatoid (4) · Dermatomyositis (4) · Microscopic Polyangiitis (4) · Recurrence (4)
Immune System Diseases (48) · Skin Diseases (48) · Skin Diseases, Vascular (48) · Skin and Connective Tissue Diseases (48) · Cardiovascular Diseases (46) · Vascular Diseases (45) · Autoimmune Diseases (40) · Vasculitis (39) · Connective Tissue Diseases (29) · Nervous System Diseases (24) · Musculoskeletal Diseases (22) · Muscular Diseases (21) · Neuromuscular Diseases (21) · Female Urogenital Diseases (12)
Cyclophosphamide (10) · fludarabine (8) · avacopan (5) · Immunotherapy, Adoptive (2) · Mycophenolic Acid (2) · Prednisone (2) · Rituximab (2) · mepolizumab (2) · Abatacept (1) · BDB001 (1) · Bendamustine Hydrochloride (1) · Celecoxib (1) · Glucocorticoids (1) · Interleukin-10 (1) · Itraconazole (1)
Amgen (6) · China Immunotech (Beijing) Biotechnology Co., Ltd. (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Fate Therapeutics (2) · Peking University Third Hospital (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · University of Pennsylvania (2) · Adicet Therapeutics (1) · Alpine Immune Sciences, Inc. (1) · Beijing GoBroad Hospital (1) · Brigham and Women's Hospital (1) · Cartesian Therapeutics (1) · Changzhou No.2 People's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (25) · China (19) · Australia (1) · France (1) · Italy (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Carol A. Langford, MD, MHS (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Guillermo J. Valenzuela, M.D. (1) · Kathy I. Perez, M.D. (1) · Kristen Lee (1) · Liyun Zhang, M.D (1) · Marc E. Rothenberg, MD (1) · Maria Antonietta D'Agostino (1) · Martin K Kankam, Doctor (1) · Michael Wechsler, MD (1) · Minghui Zhao, Postdoc (1) · Peter A. Merkel, MD, MPH (1) · Sebastian Unizony, MD (1)
PMID 20093349, PMID 24323392, PMID 38973157, PMID 38993026
U54AR057319 (1)